egle logo

Modulating Treg Cells to Balance Immunity

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.


About Us

According to Greek poet Hesiod, Aglaea (Egle) was the youngest of the Zeus Daughters Charites, symbolizing beauty, splendor, glory, and magnificence, all essential attributes to enlighten hope for patients suffering from severe diseases and to deploy unprecedent remarkable science to meet the unmet.

Inspired by the myth of Aglaea, Egle Therapeutics has been built with the sole driver of assembling the most notable scientific expertise with genuine talents to bring well-being to the patient’s community.


Who we Are

Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur, and Dr Eliane Piaggio PhD, Director of the Translational Immunotherapy Team at Institut Curie, Egle Therapeutics is developing first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.


Our Science

Egle’s scientific foundations benefits from decades of breakthrough academic research leading to unprecedented computational based IL-2 modified variants and a unique translational-based target discovery platform unveiling novel therapeutic Treg targets.

The key element of Egle’s core approach leverages of unifying therapeutic potentials of antibody specific targeting combined with the selective mechanism of action of modified cytokine for arming or disarming the most immunosuppressive Tregs to restore the immune response.

Egle deploys its first-in-class technology platforms to building a furnished drug pipeline of novel immunotherapies against Tregs with tremendous potential in the oncology and auto-immunity fields.



Luc Boblet

Co-Founder and Chief Executive Officer

  • 15+ industrial experience in therapeutics R&D, corporate business development and start-up entrepreneurship including exit.
  • Former EVP Business Dvp at HIFIBIO, Co-founder and CEO H-IMMUNE (acquired by HIFIBIO), Co-founder and CEO Pathoquest
  • Former Board member at the BioAster Technological Research Institute.
  • MSc in biotech engineering, MSc in Virology Paris VII University, trained as a PhD in Immuno Virology Paris VII University.

Eliane Piaggio Ph.D

Scientific founder & Scientific Advisor

  • 20+ experience in academic and translationnal research in immunology.
  • INSERM Research Director U932 Immunity and cancer, Head of Transimm Team (Translationnal Immunoterapy) at Institut Curie.
  • Multiple ongoing research collaborations with top tiers pharma (Genentech, Novartis, Sanofi, Transgene).
  • Former Professor of Immunology at University National University of Rosario.

Stéphane Postic

Chief Financial Officer

  • 15+ experience in finance management both in large international retail organizations and biotech companies including IPO.
  • Currently part-time CFO at DaVolterra
  • Former part time CFO at H-IMMUNE (acquired by HIFIBIO), part time CFO at Pathoquest and full time CFO of Genfit, in charge of financials including IPO on Euronext.
  • Msc in Finance Management from EM Lyon.

Board Members

Felice Verduyn - van Weegen

Partner at LSP

Felice Verduyn-van Weegen is a Partner at LSP and has joined the company early 2015. In addition to Egle therapeutics, Felice serves on the Boards of a.o. Vico therapeutics, Amolyt pharma, Evommune and AM-pharma. Prior to joining LSP, Felice was a consultant at McKinsey & Company with a primary focus on healthcare projects. Before McKinsey, she was a neuroscientist and statistical geneticist, working with the prestigious complex traits genetics group at the Broad Institute and Harvard Medical School in Cambridge, USA. Felice was awarded a Bachelor’s degree in Biological Psychology and a Master’s degree in Neuroscience from the VU University, Amsterdam. In addition, she was awarded an MBA degree from Columbia Business School, New York USA.

Vincent Brichard

Venture Partner at LSP

Vincent Brichard is Venture Partner at LSP. He was formerly Senior Vice President and member of the Executive Team of GlaxoSmithKline (GSK) and headed the Business Unit for Immunotherapeutics. He is member of scientific advisory boards and supervisory boards of several European life sciences companies active in the fields of immuno-oncology, vaccines and diagnostics. He authored more than a 100 research manuscripts in leading international journals. He studied medicine at the Louvain University in Brussels and Institute Curie in Paris, received his Ph.D. in tumor immunology at the Ludwig Institute for Cancer Research in Brussels and had the position of a Professor of Oncology at Louvain University, Brussels. He also holds an executive MBA from Harvard Business School.

Sacha Mann

Senior Partner at Takeda Ventures

Sacha Mann joined Takeda Ventures, Inc. (TVI) in June 2021, as Senior Partner, and is based in Vancouver, British Columbia. She has a decade of experience in venture investing and complimentary skills in company creation, management as biotech CEO, business development, and R&D. She has been an advisor and director for various life science companies, incubators / accelerators, and venture capital funds. Previously she was the CEO of Biosys, a venture-backed clinical stage microbiome company, and led several healthcare investments at Inventages. Prior to Inventages, Sacha was an early stage investor focused on innovation and investment at Archangels and BDC Capital. Sacha holds a BSc Honours in Chemistry from the University of British Columbia, a MSc in Biotechnology from Johns Hopkins University and a MBA from Simon Fraser University.

Jean-François Morin

Investment Director at BPI-Innobio2

Jean-François Morin is an Investment Director covering venture capital investments in biotech and medical devices companies. Jean-François currently serves on the Boards of ONA Therapeutics, Sensorion and Orphalan. Prior to joining Bpifrance, he was a Financial Manager at CDC Entreprises, a Funds Management company where he was involved in structuring several investment funds and for the portfolio monitoring, mostly in Venture Capital. He is graduate from EDHEC Business School in France.


Board Observers

Philippe Monteyne

Partner at Fund+

Dr. Philippe Monteyne MD, PhD is a Partner at the VC Fund+ in Belgium. Fund+ is an open ended Fund for long term equity investments in innovative life sciences companies with a focus on Belgium and other European Hubs. The fund wants to create sustainable shareholders’ value, contribute to the development of a leadership position of the Life Sciences sector and generate a tangible, beneficial societal impact. Dr. Monteyne has held senior positions in SmithKline Beecham, GSK, and Sanofi. He served as the Head of Global Vaccine Development at GSK for several years, and then served as Senior VP-Head of Development and CMO at GSK Rare Diseases from 2010 to 2012.Amongst his achievements, was the development and launch of GSK's Cervical Cancer Vaccine, Cervarix, the R&D work that allowed to develop Strimvelis and Tegsedi (gene therapy and oligonucleotide in rare diseases). More recently, he served as Vice President R&D France at Sanofi until early 2015. During that period, he was also Board Member of SARD (Sanofi Aventis R&D), of the LEEM (Pharmaceutical association in France "Les Entreprises du Médicament"​), of the Bioaster Insitute in Lyon, and of the « Fondation Plan Alzheimer France ». He is a Board Director of several Biotech companies, in Belgium, France and Spain. Dr. Monteyne was also visiting Professor of Neurology at the UCL (Université Catholique de Louvain), Brussels. He holds an M.D. degree and Ph.D. in Viral Immunology, both at the UCL, is a fully trained Neurologist, and has also been trained in Neuro-Immunology at Pasteur Institute in Paris.

Jacques Mizrahi

Venture Partner at Bioqube

Jacques Mizrahi is Venture Partner at Bioqube Ventures. Jacques has been trained in France (Pitié-Salpetriere, University Paris VI) and in Canada (Sherbrooke University; University of Science; Medical School) in Physiology-Pharmacology, completed by post-doctoral studies at Inserm U36/Hospital Broussais) with Prof. Pierre Corvol. He then started his career in Big Pharma; Glaxo (Paris-France), Eli Lilly (Indianapolis-USA) and Roche (Basel-Switzerland) where he spent over 18 years in R&D in Cardiovascular & Metabolic diseases as Global Therapy area Director as well as leading the Clinical Research & Exploratory Medicine group, bridging Research and clinical development up to PoC). As Global Therapy Area Head, he was a member of the Research & Development Committee in Basel. After leaving Roche, Jacques has oriented his interests towards the development of Biotechs programs via the partnerships with VCs (Aravis); boards of directors of several European Biotechs and Public institutions (Inserm Transfer, IHU Paris).

Elisa El Nouchi

Associate at BPI-Innobio2

Elisa El Nouchi is an Associate in the Life Sciences Investment team at Bpifrance. She currently serves on the Board of AlgoTherapeutix and has participated in multiple investments/refinancing through Bpifrance Funds. Prior to joining Bpifrance, she started her career in the M&A Department of a Specialty Pharmaceutical Company in Paris. She holds a PharmD from the Faculty of Pharmacy Paris-Saclay and a Master in Management from the ESSEC Business School.






Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers.

Learn More

Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda.
Egle to receive R&D milestone payment and equity funding from Takeda.

Learn More

Egle Therapeutics enters into a corporate strategic research alliance with Takeda to uncover novel tumor-specific regulatory T-cell targets and develop unique anti-suppressor-based immunotherapies.

Learn More